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Mutations of several genes encoding peroxisomal proteins have been associatedwith humandiseases. Some
of these display speciﬁc white matter abnormalities in the brain, although the affected proteins are ubiq-
uitously expressed. To better understand the etiology of peroxisomal myelin diseases, we aimed to label
these organelles in vivo and in a cell type speciﬁc fashion.We had previously shown that in oligodendrocytes
and Schwann cells numerous peroxisomes reside in the cytoplasmic channels of “non-compacted” myelin.
These organelles are smaller and biochemically distinct from non-myelin peroxisomes. Targeting peroxi-
somal functions in various cell types of the brain has demonstrated that oligodendroglial peroxisomes are
speciﬁcally important for long-term integrity of the CNS. To visualize myelin peroxisomes in intact cells and
tissues by live imaging, we have generated a novel line of transgenicmice for the expression of ﬂuorescently
tagged peroxisomes speciﬁcally in myelinating glia. This was achieved by modifying the gene for a pho-
toconvertible mEos2 with a peroxisomal targeting signal type 1 (PTS1) and generating a fusion gene with
the myelin-speciﬁc Cnp1 promoter. In the brain of resulting transgenic mice, peroxisomes are selectively
labeled in oligodendrocytes. In this novel genetic tool, photoconversion of single peroxisomes from green to
red ﬂuorescence can be used tomonitor the fate of single organelles and to determine the dynamics of PTS1-
mediated protein import in the context of myelin diseases that affect peroxisomal functions.
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Peroxisomes are a group of heterogeneous organelles for com-
partmentalized anabolic and catabolic reactions, speciﬁcally in lipid
metabolism [1]. Diversity of peroxisomes has been observed
frequently in different tissues and suggests functional and cell type-
speciﬁc specializations of this organelle, reﬂecting also different
metabolic demands [2]. In the central nervous system (CNS)
neuronal and glial cell types differ in the content of several
peroxisomal proteins, including key enzymes such as catalase,
D-aspartate oxidase, and acyl-CoA oxidase [3,4].
The most severe human peroxisomal disorder is the Zellweger
syndrome (ZS) that is lethal in the postnatal period [5]. Underlying
this heterogeneous group of disorders is usually a complete
peroxisomal dysfunction caused by mutations in one of several
essential peroxins (PEX). PEX proteins are involved in peroxisomal
biogenesis, with PEX5 being a central participant in this process.
This cytosolic cycling receptor is necessary for the import of glob-
ular proteins bearing a type 1 peroxisomal targeting signal (PTS1).
The C-terminal tripeptide SKL is the prototype of a PTS1 [6]. Sincelicense.
S. Richert et al. / Biochimie 98 (2014) 127e134128its discovery the SKL sequence has been successfully used in many
systems to visualize peroxisomes in cultured cells. This was ach-
ieved by expression of fusion proteins harboring the SKL motif at
the C-terminus of various reporter proteins [7,8]. Recently, a red
ﬂuorescent protein (mRuby) was reported, in which a related
C-terminal sequence (GRL) emerged as a functional PTS that
allowed visualizing peroxisomes in cultured cells [9].
The pronounced neurodegeneration seen in peroxisomal dis-
orders has led to the extensive investigation of peroxisomal func-
tions in the nervous system. Several mouse mutants were
generated that lack either a PEX protein or another essential protein
of speciﬁc peroxisomal functions [10e21]. More recently, cell type-
speciﬁc ablation of most peroxisomal functions was achieved in
various neural cell types [22e24]. This revealed a key function of
oligodendroglial peroxisomes in maintaining myelin and axonal
integrity of the CNS.
To enable the analysis of peroxisomes in myelinating cells
in vivo, ex vivo and by live cell imaging of intact tissue and primary
cultured cells, we have generated and characterized transgenic
mice with ﬂuorescently tagged peroxisomes. The myelin-speciﬁc
Cnp1 promoter was used to drive expression of the transgene in
myelinating cells [25]. Peroxisomal targeting was achieved by
fusion of C-terminal SKL to the coding sequence of photo-
convertible mEos2 protein, a variant of EosFP [26,27].2. Material and methods
2.1. Mouse genetics
A standardized fusion 3-step polymerase chain reaction (PCR)
was performed using four primers, a Cnp1 promoter plasmid, and a
plasmid containing the coding sequence of mEos2 served as tem-
plates DNA (primer sequences are available upon request) [25]. The
generated fragment contained 396 bp of the Cnp1 promoter
sequence downstream of the AﬂII restriction site and the complete
coding sequence of mEos2. The antisense primer of mEos2 was
designed such that 9 bp (encoding Ser, Lys, Leu for peroxisomal
targeting) were inserted directly before the stop codon and a BamHI
restriction site was added downstream of the stop codon. It was
ligated into pGEM-T vector (Promega) for TA-cloning and by use of
AﬂII and BamHI restriction sites cloned into the Cnp1 promoter
plasmid. Restriction sites, XbaI (upstream) and ClaI (downstream),
ﬂanked a 5.1 kb sequence including Cnp1 promoter (3.9 kb) [28],Fig. 1. Identiﬁcation of genomic transgene insertion and of mEos2 expression in mice. (A) S
the mEos2 coding sequence cloned into the original start codon of CNP1. 9 extra base pairs
and Leu), a type 1 peroxisomal targeting signal (PTS1). Downstream the sequence is ﬂanked
exon 0 of the CNP gene. (B) Genotyping PCR by use of primers 1 and 2 showing a fragment o
not from wild-type controls (WT).mEos2 coding sequence with PTS1 (687 bp), and polyadenylation
signal sequence of Simian virus 40 (120 bp). After restriction digest
with XbaI and ClaI enzymes the DNA was puriﬁed by QIAquick spin
columns (Qiagen). The linearized DNA was injected into C57BL/6N
mouse oocytes according to standard procedures.
For genotyping, genomic DNA was isolated from tail biopsies
using the DNeasy 96 tissue kit (Qiagen) according to the manu-
facturer’s directions. Routine genotyping PCR was performed with
sense (50-CTTCTTACACAGGCCACCATGAGTGCG-30) and antisense
primers (50-GGATCCTTACTTAGTTAAAGCTTGGATCGT-30) yielding a
722 bp fragment, containing the mEos2 sequence.
Animal experiments were carried out in compliance with
approved animal policies of the MPI of Experimental Medicine.2.2. Histology
Mice were anesthetized with avertin (100 ml/10 g bodyweight)
and perfused intracardially with HBSS (Lonza) followed by 4%
paraformaldehyde (PFA) in 100 mM phosphate buffer. After dissec-
tion, brains were postﬁxed in the same ﬁxative overnight. Sagittal
vibratome sections of 40e50 mm were generated (Leica VT 1000S,
Leica Instruments, Nussloch, Germany) and used for immunohis-
tochemical stainings. Brain sections were permeabilized in 0.4%
Triton in PBS for 30 min. Blocking was performed for 30 min in 4%
Horse serum (HS) and 0.2% Triton in PBS. Primary antibody incu-
bationwas carried out overnight at 4 C in 1% HS and 0.05% Triton in
PBS. Incubation of ﬂuorescently labeled secondary antibodies was
carried out at room temperature for 2 h in 1.5%HS and sectionswere
mounted in AquaPolymount (Polysciences, Warrington, PA).
Antibodies were used as follows: ACAA1 (ProteinTech Group)
1:200; GFAP (DAKO) 1:500; Iba1 (Wako) 1:1000; Lamp1 (Phar-
Mingen) 1:200; MRP-S21 (Antibodies-online) 1:50; NeuN (Milli-
pore) 1:100; Olig2 (provided by J. Alberta [29]) 1:200; PMP70
(Abcam) 1:600; PMP70 (SigmaeAldrich) 1:400, and secondary
ﬂuorescence-conjugated Alexa-488, Alexa-555 (1:2000, Invi-
trogen) or DyLight 633 (1:200, YO Proteins).2.3. Cell culture
Oli-neu cells, an oligodendroglial precursor cell line, were ob-
tained from Jacqueline Trotter (university of Mainz). Cultivation
and electroporation of cells was performed as described earlier
[30,31].tructure of the Cnp-mEos2-PTS1 transgene containing 3.9 kb of the CNP1 promoter and
are inserted upstream adjacent to the stop codon, encoding three amino acids (Ser, Lys
by a polyadenylation signal sequence of the Simian virus 40 (SV40 polyA). E0 indicates
f the expected size when template DNA was obtained from transgenic animals (TG) but
S. Richert et al. / Biochimie 98 (2014) 127e134 129Mouse embryonic ﬁbroblasts were generated from wild-type
mouse embryos at embryonic day 14.5 (E14.5) according to stan-
dard procedures described elsewhere [32]. Fibroblasts for live cell
imaging were seeded and imaged in m-dish cell culture imaging
dishes (Ibidi, Germany) coated with poly-L-lysin. Transfection with
mEos2-PTS1 construct (in the pEGFP-N1 vector, Clonetech) was
carried out with Lipofectamin2000 (Invitrogen) according to
manufacturer’s directions. Cells were cultured in a humidiﬁed
incubator (5% CO2 at 37 C). For imaging cells were transferred to a
temperature and CO2 controlled microscope incubation chamber.2.4. Imaging and image processing
Fluorescent images were acquired with an inverted Zeiss
Axio Observer. For green ﬂuorescence mEos2-PTS1 signal was
excited using a 426e446 nm bandpass ﬁlter, and emission was
recordedwith a 520e550 nm bandpass ﬁlter. For red ﬂuorescence a
535e557 nm bandpass ﬁlter was used, and emission was recordedFig. 2. mEos2 expression in the brain of Cnp-mEos2-PTS1 transgenic mice. (A) Sagittal
vibratome brain section of a transgenic mouse at 2 months displays high expression of
the transgene particularly in white matter structures. Scale bar, 1.5 mm. Middle and
bottom panels show magniﬁcations of the corpus callosum (CC), the anterior
commissure (AC), cerebellar white matter (CB), and the cerebral cortex (CTX). Scale
bars, 20 mm. (B) Expression is also abundant in the spinal cord as visualized by ﬂuo-
rescence of a spinal cord cross-section (left; Scale bar, 0.5 mm) and magniﬁcation of
spinal cord white matter (WM; right). Scale bar, 20 mm.with a 570e640 nm bandpass ﬁlter. Conversion of mEos2-PTS1
proteinwas carried out with excitation Filter G 365, illuminating for
1 swhenusing a 63objective.10 s of illuminationwere required for
photoconversion using a 10 objective.
Images were processed with ImageJ software, version 1.47u. Co-
localization of Olig2-positive nuclei and perinuclear mEos2 signal
was measured with Imaris software, version 7.52 (Bitplane AG,
Switzerland) and calculations were performed with GraphPad
Prism 5.
3. Results
3.1. Generation of transgenic mice
A fusion polymerase chain reaction (PCR) was performed to
generate a 1.1 kb mEos2 cDNA fragment terminated by restriction
sites suitable for subsequent cloning (Fig. 1A). This fragment con-
tained the coding sequence of mEos2 with a 9 bp 30 extension
encoding the SKL peroxisomal targeting signal (PTS1). The frag-
ment was inserted into a plasmid with the promoter of the 20, 30-
cyclic nucleotide phosphodiesterase gene (Cnp1). To prevent
mitochondrial targeting, we removed a 57 bp fragment upstream of
the start codon for the CNP1 isoform, thereby eliminating the
N-terminal mitochondrial targeting sequence of the CNP2 isoform
[33]. Downstream the transgene was ﬂanked by the SV40 poly-
adenylation signal (Fig. 1A). After injection of the linearized frag-
ment into fertilized C57BL/6N oocytes, we obtained ﬁve potential
founders (F0) from twenty-two mice, as assessed by PCR analysis
(Fig. 1B). Transgenic animals were born at the expected Mendelian
frequency and showed no obvious differences from wild-type lit-
termates. Two lines were expanded and characterized in more
detail. In the following, we concentrate on one line of Cnp-mEos2-
PTS1 mice that was optimally suited for studying myelin-
associated peroxisomes.
3.2. Spatio-temporal expression pattern of Cnp-mEos2-PTS1
Fluorescence microscopic analysis of vibratome sections
demonstrated high expression of mEos2 in the adult central ner-
vous system, with pronounced localization of labeled peroxisomes
in white matter tracts, such as corpus callosum, anterior commis-
sure, and cerebellar white matter (Fig. 2). With respect to expres-
sion level, we noted a gradient most evident on sagittal sections
with mEos2 expression stronger in caudal regions than in rostral
regions (Fig. 2A). However, no region of brain and spinal cord was
free of labeled peroxisomes (Fig. 2B). Similar to the developmental
expression of CNP and other myelin proteins, mEos2þ puncta were
readily detectable in spinal cord and in brain stem at postnatal day
7 (P7), and only later in frontal brain areas (data not shown) [34].
After P14 the expression pattern of mEos2 mice was essentially the
same as in the CNS of adult transgenic mice. However, at this early
stage the expression level was lower than in older mice, which
maintained the adult expression levels as visualized by ﬂuores-
cence intensity for at least 6 months (data not shown).
As expected, double-staining for the oligodendroglial tran-
scription factor Olig2, revealed that the majority of cells in the
oligodendroglial lineage were mEos2 positive (Fig. 3A). Most of this
signal was punctate and perinuclear, but single mEos2þ puncta
were also frequent deep in the glial cell processes. These puncta are
most likely equivalent to single peroxisomes residing in “myelinic
channels”, such as the cytoplasm of non-compacted myelin at the
adaxonal inner mesaxon [35].
Next, we quantiﬁed Olig2-positive nuclei that were associated
with perinuclear mEos2 signal. All measured CNS regions (cere-
bellar white matter, anterior commissure, corpus callosum, and
S. Richert et al. / Biochimie 98 (2014) 127e134130cerebral cortex) showed a marked (60e80%) co-localization of
Olig2 andmEos2 in the same oligodendrocyte lineage cells (Fig. 3B).
In contrast, we never observed perinuclear mEos2 signals in GFAP-
positive astrocytes, in Iba1-positive microglia/macrophages, or in
NeuN-positive neurons (Suppl. Fig. 1). Taken together, these data
suggest that we have achieved cell-speciﬁc expression of mEos2 by
oligodendroglial cells (and some of their precursors) in the CNS of
Cnp-mEos2-PTS1 mice.
In contrast, teased ﬁber preparations of the sciatic nerve showed
an extremely weak mEos2-signal (data not shown). This is consis-
tent with the very low expression level of CNP in myelinating
Schwann cells of the PNS [36]. Several other tissues tested,
including heart, lung, liver, kidney, and muscle, did not reveal any
ﬂuorescent signal in Cnp-mEos2-PTS1 transgenic mice (data not
shown). However, we noted robust mEos2-expression in some cells
of spleen and testis (Suppl. Fig. 2), in agreement with published
data on enzymatic activity of CNP or immune staining of CNP
[37,38]. Although, we did not perform co-localization studies with
peroxisomal marker proteins in these tissues, the punctate signal in
these tissues indicated targeting of peroxisomes.Fig. 3. mEos2 expression by Olig2-positive brain cells in Cnp-mEos2-PTS1 transgenic
mice. (A) Vibratome brain sections immune-stained for nuclear oligodendroglial maker
protein Olig2 (red) shows high association of oligodendroglial cells with mEos2 ﬂuo-
rescence (green). Scale bar, 10 mm. (B) Graphic illustration of the high amount (60%)
of Olig2-positive cells that express mEos2. It was quantiﬁed in different white matter
regions (cerebellar white matter, CB; anterior commissure, AC; corpus callosum, CC)
and in the cortex (CTX). Values are expressed as mean percentage  SD; n ¼ 3.3.3. Peroxisomal targeting
To assess whether the ﬂuorophore is exclusively targeted to
peroxisomes in vivo, we performed subcellular co-localization
studies on brain vibratome sections from transgenic mice (Fig. 4).
Antibodies recognizing peroxisomal membrane protein 70
(PMP70) and peroxisomal acetyl-CoA acyltransferase 1 (ACAA1)
conﬁrmed targeting and localization of mEos2 in peroxisomes
(Fig. 4A, B). To assess any additional targeting of the fusion protein
to other organelles, we visualized mitochondria by co-staining of
the mitochondrial ribosomal protein S21 (MRP-S21). This showed
that mEos2 was never targeted to mitochondria (Fig. 4C). Also, the
lysosome-associated membrane protein 1 (Lamp1), was never co-
localized with mEos2 (Fig. 4D). Thus, by these criteria targeting of
mEos2-PTS1 is speciﬁc to the peroxisomal compartment.3.4. Photoconversion of mEos2
mEos2 was designed such that exposure to UV light converts the
original green ﬂuorescence (max. at 519 nm) into emission of red
light (max. at 584 nm) [27]. However, the maxima of emission and
excitation are dependent on the local pH, which is different in
peroxisomes and cytoplasm [39,40]. We therefore investigated theFig. 4. Exclusive peroxisomal targeting of mEos2-PTS1 in vivo. Depicted are ﬂuores-
cence micrographs of a transgenic mouse brain cortex. (A, B) mEos2-PTS1 (green)
shows co-localization with the peroxisomal enzyme acetyl-CoA acyltransferase
(ACAA1; red) and with peroxisomal membrane protein 70 (PMP70; red). (C, D) In
contrast, no co-localization is observed with mitochondrial ribosomal protein S21
(MRP-S21; red) or with lysosome associated protein 1 (Lamp1; red). DAPI-stained
nuclei are shown in blue (right). Scale bar, 5 mm.
Fig. 5. Photoconversion of mEos2 in the transgenic mouse brain and in primary cells. Before irradiationwith UV light, ﬂuorescence of the ﬂuorophore is strong in the green emission
range, but almost absent in the red spectrum (left). Green ﬂuorescence is reduced in favor of red ﬂuorescence after photoconversion (right). (A) Corpus callosum (scale bar, 200 mm)
and (B) cerebellum (scale bar, 200 mm) are shown. Insets magnify cerebellar white matter. (C) Photoconversion is demonstrated on single cell level in the corpus callosum with
insets to enable visualization of single organelles. Scale bar, 5 mm. (D) Fluorescence within a rectangular region of interest of a transfected mouse ﬁbroblast was switched to
demonstrate photoconversion of single peroxisomes. Scale bar, 10 mm.
S. Richert et al. / Biochimie 98 (2014) 127e134 131emission and excitation spectra of mEos2 inside peroxisomes of live
cells.
We transfected oli-neu cells, a well-established oligodendroglial
cell line [30] with the same DNA construct that was used for the
generation of Cnp-mEos2-PTS1 mice. After 2 days, we performed
“lambda scans” with excitation between 470 nm and 670 nm and a
step-width of 10 nm to measure the emission spectrum using a
confocal laser-scanning microscope (LSM; data not shown). Next,
we adapted a protocol for photoconversion of mEos2-PTS1 in PFA-
ﬁxed (and unﬁxed) brain sections, using a wide-ﬁeld ﬂuorescence
microscope (Fig. 5). The switch from green to red emission was
achieved after irradiation with UV light (340e390 nm) in all brain
areas, including corpus callosum and cerebellar white matter
(Fig. 5A, B). The converted ﬂuorescence of single peroxisomes was
readily evident by a magniﬁed view of oligodendrocytes in the
corpus callosum (Fig. 5C).We also attempted to convert the ﬂuorescence of only a subset
of peroxisomes within a single cell. To this end mEos2-PTS1
transfected primary mouse ﬁbroblasts were investigated using an
inverted ﬂuorescence microscope equipped for live cell imaging
(Suppl. Video 1). A subcellular region of interest was irradiatedwith
UV light using a rectangular diaphragm resulting in discrete
number of peroxisomes with red ﬂuorescence, while the majority
of organelles exhibited green ﬂuorescence (Fig. 5D).
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.biochi.2013.10.022.
3.5. mEos2-PTS1 expression in oligodendrocytes is not toxic
To analyze possible toxic effects of transgene expression in
the brains of 12 months old mice, we searched for condensed
nuclei (indicative of apoptosis) that are visible by H&E staining.
Fig. 6. Absence of reactive gliosis in the brain of transgenic mice aged 12 months. Immune-staining for (A) microglial Iba 1 and (B) astroglial glial ﬁbrillary acidic protein (GFAP) do
not show differences regarding expression level, morphology, or distribution of glial cells in the corpus callosum (top), the cerebellum (middle), and in the cortex (bottom) of
transgenic mice. Scale bars, 50 mm.
S. Richert et al. / Biochimie 98 (2014) 127e134132In addition we used the terminal transferase dUTP nick end la-
beling (TUNEL) technique to mark nuclei with fragmented DNA.
By either method, we found no difference between transgenic
and wild-type mice in the frequency of apoptotic cells. We also
obtained no evidence for axonal perturbations, such as amyloid
precursor protein (APP)-positive swellings that are a feature of
peroxisomal mutants (data not shown) [22]. When studying the
brains of 12 months mice by immunohistochemistry, there was
no difference in the distribution, density and morphology of as-
trocytes and microglial cells (Fig. 6). Up to one year of age we did
not notice any sign of abnormal cage behavior (not shown).
Taken together, this suggests that Cnp-mEos2-PTS1 transgenic
mice will be an useful tool to visualize peroxisomes in combi-
nation with neurological disease genes.
4. Discussion
The generation of mice with ﬂuorescently labeled peroxi-
somes in oligodendrocytes was achieved with the myelin-speciﬁc
Cnp1 promoter that drives expression of mEos2 in oligodendro-
cytes. Fusion of the tripeptide SKL (a type 1 peroxisomal tar-
geting signal; PTS1) at the C-terminus of the mEos2 protein has
efﬁciently and exclusively mediated the targeting of the ﬂuo-
rophore into peroxisomes in vivo. We could show that transgene
expression in the central nervous system of these mice is
restricted to oligodendrocyte lineage cells. Independent of the
CNS region analyzed, between approximately 60e80% of alloligodendrocyte lineage cells were positive for the ﬂuorophore
(but not 100%, see below). The expression was particularly high
in white matter tracts, but also present in the majority of gray
matter oligodendrocytes. Since the ﬂuorescence was already
detectable in many regions at age P7 and the ﬁnal expression
pattern was established by P14, these transgenic mice appear
suitable for many developmental studies. Speciﬁcally, the anal-
ysis of peroxisomes in the CNS of adult and aged mice and in the
context of neurodegenerative diseases will be possible, because
there is no obvious toxicity of transgene expression at all ages
studied (up to 12 months).
We deﬁned oligodendrocyte lineage cells by the expression of
Olig2 as a marker, which also stains oligodendrocyte precursor cells
(OPC) prominently. The Cnp1 promoter is active in mature oligo-
dendrocytes, but only in 50% of adult OPC (Saab et al., in prepara-
tion). This suggests that virtually all mature oligodendrocytes
express the Cnp1-driven transgene, as expected from similar
transgenic studies [41]. However due to the low expression level of
the Cnp1 promoter in Schwann cells, these mice may be less suited
for PNS analyses.
An advantage of mEos2 over other GFP-like reporter proteins is
the convertible ﬂuorescence changing the emission from the green
to the red spectrum of light. We have shown that mEos2 ﬂuores-
cence can be switched within a small region of interest to target
only a subset of peroxisomes within a cell. It is theoretically
possible to switch the ﬂuorescence of only a single peroxisome in
the process of an oligodendrocyte or within a myelin internode,
S. Richert et al. / Biochimie 98 (2014) 127e134 133where the density of organelles is sufﬁciently low. This will enable
us to follow the fate of single organelles by live imaging. Another
application of the photoconvertible properties of mEos2 will be a
monitoring of the rate of peroxisomal biogenesis and the fate of this
organelle, similar to a “pulse-chase” experiment. When all resident
peroxisomes are simultaneously switched to red, the appearance of
newly formed (green) peroxisomes can be easily monitored and the
half-live of (red) peroxisomes and their elimination by autophagy
can be quantiﬁed.
Ligands of peroxisome proliferator-activated receptors (PPARs)
are able to induce peroxisome proliferation and possibly biogenesis
in liver cells [42,43], but little is known about similar effects on
oligodendrocytes in which peroxisomes serve a neuroprotective
function [22]. The Cnp-mEos2-PTS1 transgenic mouse will enable us
to explore PPAR signaling and other drug effects on peroxisome
biogenesis and turnover in the brain. Similarly, the rate of peroxi-
somal protein import can be determined in situ, which is of rele-
vance for speciﬁc peroxisomal defects, such as in X-linked
adrenoleukodystrophy, a disease that has been suspected to reﬂect
secondary organelle dysfunctions [22,44].
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